ERT’s income falls in Q2

By Nick Taylor

- Last updated on GMT

Related tags Ert Contract research organisations Revenue Contract research organization Epro

eResearch Technologies (ERT) posted a Q2 operating income of $4.8m (€3.4m), down from $10.8m last year, and attributed the decline to companies delaying thorough QT trials.

Regulatory guidance means that thorough QT trials must still be conducted but companies are delaying them until later in the drug’s development.

This, and delayed decision making by pharmas and contract research organisations (CRO), has impacted upon the cardiology and eClinical company’s operations.

Despite net revenues falling from $35.5m in Q2 2008 to $24.2m in its latest results Michael McKelvey, CEO of ERT, remains optimistic and believes the fundamentals of the industry remain strong.

He explained that ERT has had productive “discussions with key pharmaceutical and biotechnology companies on strategic outsourcing relationships​” but there is still uncertainty about clients’ spending.

Bookings are still down on 2008 and although ERT believes the second half of this year will be better the company has a cautious outlook.

Strategic shift

ERT sold its electronic data capture (EDC) business to OmniComm Systems in June. The business generated revenues of $2.5m in the first six months of 2009.

In a conference call with investors McKelvey explained that the company exited the EDC market because “it is clear that a more significant and focused investment is required to be successful​”.

This has freed up resources to focus on its cardiac services and electronic patient reported outcomes (ePRO) businesses. ERT believes that there are opportunities for growth in the ePRO market, in particular as a tool to asses the suicide risk of a new drug.

Phase Forward is among the other companies that have recognised the potential of the ePRO market and recently bought Maaguzi to increase its presence in the sector.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more